Form 4 · Filed May 27, 2026, 08:05 PM UTC
KALV/KalVista Pharmaceuticals, Inc.
Sweeny Nicole — Chief Commercial Officer
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
3 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 26, 2026 | S | sell | 1,489 | $27 | $39,872 | 59,291 |
| May 22, 2026 | M | other | 5,000 | — | — | 60,780 |
| May 22, 2026 | M | other | 5,000 | — | — | 40,000 |
Source: SEC EDGAR raw filing ↗ · Accession 0001827505-26-000005